Scott Struthers
Founder at CRINETICS PHARMACEUTICALS, INC.
Net worth: 49 M $ as of 29/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Stephen Betz | M | 58 | 21 years | |
| Wendell Wierenga | M | 76 | 14 years | |
| Randy Schreckhise | M | - |
The San Diego Entrepreneurs Exchange
| - |
| Stephen Sherwin | M | 75 | 25 years | |
| Rogério Vivaldi Coelho | M | 60 | 2 years | |
| Dana Pizzuti | M | 69 | 2 years | |
| Stephanie Okey | F | 64 | 5 years | |
| Alan Krasner | M | 60 | 6 years | |
| Weston Nichols | M | 39 | 6 years | |
| Marc Wilson | M | 45 | 6 years | |
| Caren Deardorf | F | 59 | 2 years | |
| Paul Grayson | M | - |
Radionetics Oncology, Inc.
 Radionetics Oncology, Inc. Pharmaceuticals: MajorHealth Technology Radionetics Oncology, Inc. is a clinical stage radiopharmaceutical company based in Menlo Park, CA. Radionetics Oncology, Inc. focuses on the discovery and development of novel radiotherapeutics for the treatment of various oncology indications. Radionetics Oncology spun out of Crinetics Pharmaceuticals and is supported by Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Investments. The company is advancing a pipeline of small molecule radioligands that target G-protein coupled receptors to treat a wide range of cancers, including adrenocortical carcinoma, breast cancer, and lung cancer. The company's platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes selectively to tumors expressing peptide receptors. The company's pipeline consists of multiple lead drug candidates, and they are conducting additional drug discovery efforts in collaboration with Crinetics Pharmaceuticals. The market for radiopharmaceuticals is expected to rise to $12.6 billion by 2027. The company was founded by Scott R. Struthers, and Paul A. Grayson has been the CEO since 2024. | - |
| Leslie Norwalk | F | 58 | 26 years | |
| Camille Bedrosian | M | 71 | 4 years | |
| Matthew Fust | M | 59 | 6 years | |
| Richard Pops | M | 62 | 26 years | |
| Daniel J. Estes | M | 43 |
Radionetics Oncology, Inc.
Radionetics Oncology, Inc. Pharmaceuticals: MajorHealth Technology Radionetics Oncology, Inc. is a clinical stage radiopharmaceutical company based in Menlo Park, CA. Radionetics Oncology, Inc. focuses on the discovery and development of novel radiotherapeutics for the treatment of various oncology indications. Radionetics Oncology spun out of Crinetics Pharmaceuticals and is supported by Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Investments. The company is advancing a pipeline of small molecule radioligands that target G-protein coupled receptors to treat a wide range of cancers, including adrenocortical carcinoma, breast cancer, and lung cancer. The company's platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes selectively to tumors expressing peptide receptors. The company's pipeline consists of multiple lead drug candidates, and they are conducting additional drug discovery efforts in collaboration with Crinetics Pharmaceuticals. The market for radiopharmaceuticals is expected to rise to $12.6 billion by 2027. The company was founded by Scott R. Struthers, and Paul A. Grayson has been the CEO since 2024. | - |
| Jacqueline Pomfret Kirby | F | - | 1 years | |
| James Hassard | M | 58 | 2 years | |
| Adriana Cabré | F | - | 4 years | |
| Jeff Knight | M | 53 | 3 years | |
| Matt McDowell | M | - | - | |
| Brian Russell | M | - | 2 years | |
| Michael Monahan | M | - | 6 years | |
| Garlan Adams | F | - | 3 years | |
| Chris Robillard | M | - | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Errol de Souza | M | 70 | 6 years | |
| Corinne Nevinny | F | 64 | 14 years | |
| Lawrence Steinman | M | 76 | 8 years | |
| Nishan de Silva | M | 51 |
Radionetics Oncology, Inc.
Radionetics Oncology, Inc. Pharmaceuticals: MajorHealth Technology Radionetics Oncology, Inc. is a clinical stage radiopharmaceutical company based in Menlo Park, CA. Radionetics Oncology, Inc. focuses on the discovery and development of novel radiotherapeutics for the treatment of various oncology indications. Radionetics Oncology spun out of Crinetics Pharmaceuticals and is supported by Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Investments. The company is advancing a pipeline of small molecule radioligands that target G-protein coupled receptors to treat a wide range of cancers, including adrenocortical carcinoma, breast cancer, and lung cancer. The company's platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes selectively to tumors expressing peptide receptors. The company's pipeline consists of multiple lead drug candidates, and they are conducting additional drug discovery efforts in collaboration with Crinetics Pharmaceuticals. The market for radiopharmaceuticals is expected to rise to $12.6 billion by 2027. The company was founded by Scott R. Struthers, and Paul A. Grayson has been the CEO since 2024. | 2 years |
| Jack Nielsen | M | 60 | 2 years | |
| Patricia Lady | F | 65 | 2 years | |
| Stephen W. Kaldor | M | 62 | 6 years | |
| Mason W. Freeman | M | 73 | 4 years | |
| Yun Fei Zhu | M | - | - | |
| W. Thomas Mitchell | M | 77 | 14 years | |
| Paul W. Hawran | M | 71 | 14 years | |
| Richard Ranieri | M | 71 | 3 years | |
| Ana Karin Kusnetzow | M | - | - | |
| Margaret E. Valeur-Jensen | M | 67 | - | |
| Gina Ford | M | - | 2 years | |
| Michelle Martin | F | - | 5 years | |
| William Mccarthy | M | - | 1 years | |
| Ajay Madan | M | 56 | 6 years | |
| Zachary Hornby | M | 45 | 2 years | |
| Yang Sai | M | - | 5 years | |
| Niel C. Hoglen | M | - | 2 years | |
| Mahendra Shah | M | 79 | 3 years | |
| Barbara M. Finn | F | - | - | |
| Stefan Proniuk | M | 53 | 6 years | |
| Stephen G. Marcus | M | - | 2 years | |
| Stefen A. Boehme | M | - | 8 years | |
| Carol A. Baum | F | 65 | 5 years | |
| David Hinkle | M | - | 3 years | |
| Thomas J. Joyce | M | 64 | 2 years | |
| John W. Beck | M | 64 | 4 years | |
| Henry Y. Pan | M | 77 | 5 years | |
| Adrian Adams | M | 73 | 2 years | |
| Tim Coughlin | M | 57 | 15 years | |
| Christopher Flint O'Brien | M | 67 | 13 years | |
| Robert J. Little | M | 74 | 3 years | |
| Robert Flath | M | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 62 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Scott Struthers
- Personal Network
